Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess efficacy and safety in combination of resminostat and
sorafenib in Asian patients with advanced HCC previously untreated with systemic
chemotherapy.